Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) Income from Non-Controlling Interests (2022 - 2024)

Jaguar Health (JAGX) has disclosed Income from Non-Controlling Interests for 3 consecutive years, with -$136000.0 as the latest value for Q2 2024.

  • Quarterly Income from Non-Controlling Interests rose 3.55% to -$136000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was -$543000.0 through Jun 2024, up 49.54% year-over-year, with the annual reading at -$563000.0 for FY2025, 25.82% up from the prior year.
  • Income from Non-Controlling Interests for Q2 2024 was -$136000.0 at Jaguar Health, up from -$142000.0 in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was -$23000.0 in Q2 2022, with the low at -$651000.0 in Q4 2022.
  • Average Income from Non-Controlling Interests over 3 years is -$182000.0, with a median of -$140000.0 recorded in 2023.
  • Peak annual rise in Income from Non-Controlling Interests hit 78.65% in 2023, while the deepest fall reached 513.04% in 2023.
  • Over 3 years, Income from Non-Controlling Interests stood at -$651000.0 in 2022, then surged by 78.65% to -$139000.0 in 2023, then grew by 2.16% to -$136000.0 in 2024.
  • According to Business Quant data, Income from Non-Controlling Interests over the past three periods came in at -$136000.0, -$142000.0, and -$139000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.